Equirus Flags Near-Term Valuation Overhang on Astral as Market Assigns Separate Multiples Post-Demerger

The Quick Take

• Equirus Securities flagged a near-term stock overhang on Astral as investors recalibrate separate multiples for the pipes-and-adhesives and chemicals businesses post-demerger.
• The market is in valuation discovery mode as it assesses what earnings multiple to apply to each resulting entity before they trade independently.
• Analyst targets have been revised to incorporate the demerger transition risk and uncertainty until Astral Chemie lists as a standalone stock.

Astral shares fell following the demerger announcement as Equirus Securities identified a near-term stock overhang rooted in multiple uncertainty. Prior to the demerger, Astral was valued as a blended building materials company encompassing CPVC piping, adhesives, and specialty construction chemicals. The demerger forces the market to disaggregate this valuation and assign separate multiples to two businesses with different growth trajectories, margin profiles, and capital requirements. Until Astral Chemie begins trading independently and analysts rebuild separate earnings coverage, the combined stock lacks a clear valuation anchor, creating the near-term overhang that Equirus correctly identifies.

Near-term stock overhangs following demerger announcements are a documented pattern in Indian equity markets. The process typically involves an initial decline as valuation uncertainty dominates, a stabilisation period as analysts rebuild separate coverage models, and a recovery or re-rating as the sum-of-parts value becomes clearer. For Astral, the critical question is whether assigning specialty chemicals multiples to Astral Chemie and building materials multiples to Astral Limited produces a combined value above the pre-demerger blended multiple. Indian specialty chemicals companies command 35-50x PE premiums versus building materials at 25-35x, suggesting the demerger could unlock meaningful value if Astral Chemie demonstrates standalone margin quality.

Watch for the demerger scheme approval timeline and the record date for Astral Chemie share allocation, which are the most immediate event-driven catalysts for resolving the near-term overhang. The first set of Astral Chemie standalone financial disclosures post-listing will be the decisive data point: EBITDA margins and return on capital employed for the chemicals business will determine whether the premium multiple thesis is justified. The macro variable is the Indian infrastructure and construction cycle: government housing and infrastructure spending drives demand for Astral piping and adhesives simultaneously with construction chemicals, meaning both entities are correlated to the same underlying demand driver, which limits the diversification benefit investors might otherwise assign to the demerger.

Synthesized from 1 source.